Skip to main content
. 2023 Nov 9;16:923–935. doi: 10.2147/OTT.S427942

Figure 7.

Figure 7

The relationship between the decline of carbohydrate antigen 19–9 (CA19-9) and the prognosis of pancreatic cancer who received a combination of gemcitabine plus nab-paclitaxel (GnP) chemotherapy and immunotherapy, (A) overall survival (OS); (B)progression-free survival (PFS).